AU2001234962A1 - Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof - Google Patents

Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof

Info

Publication number
AU2001234962A1
AU2001234962A1 AU2001234962A AU3496201A AU2001234962A1 AU 2001234962 A1 AU2001234962 A1 AU 2001234962A1 AU 2001234962 A AU2001234962 A AU 2001234962A AU 3496201 A AU3496201 A AU 3496201A AU 2001234962 A1 AU2001234962 A1 AU 2001234962A1
Authority
AU
Australia
Prior art keywords
inhibitors
mixtures
methods
complement
caspase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234962A
Inventor
William L Fodor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2001234962A1 publication Critical patent/AU2001234962A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
AU2001234962A 2000-02-10 2001-02-09 Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof Abandoned AU2001234962A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18147800P 2000-02-10 2000-02-10
US60/181,478 2000-02-10
PCT/US2001/004137 WO2001058526A2 (en) 2000-02-10 2001-02-09 Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2001234962A1 true AU2001234962A1 (en) 2001-08-20

Family

ID=22664433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234962A Abandoned AU2001234962A1 (en) 2000-02-10 2001-02-09 Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof

Country Status (5)

Country Link
US (1) US20050036991A1 (en)
EP (1) EP1253946A2 (en)
AU (1) AU2001234962A1 (en)
CA (1) CA2399969A1 (en)
WO (1) WO2001058526A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232866A1 (en) * 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
CA3035432A1 (en) * 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CN105683759B (en) 2013-08-07 2019-03-29 瑞颂医药公司 Atypia hemolytic uremic syndrome (aHUS) biomarker protein
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
JP2017515811A (en) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド Anti-factor D antibody variants and methods of use thereof
JP2018536650A (en) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド Anti-factor D antibody variant conjugates and uses thereof
JP2018534930A (en) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド Anti-factor D antibodies and conjugates
AU2016344133A1 (en) 2015-10-30 2018-05-17 Genentech, Inc. Anti-Factor D antibody formulations

Also Published As

Publication number Publication date
CA2399969A1 (en) 2001-08-16
US20050036991A1 (en) 2005-02-17
WO2001058526A9 (en) 2002-10-24
WO2001058526A3 (en) 2002-05-16
WO2001058526A2 (en) 2001-08-16
EP1253946A2 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2001249918A1 (en) Inhibitors of inflammation and reperfusion injury and methods of use thereof
PL356066A1 (en) Caspase inhibitors and uses thereof
TWI318207B (en) Carbamate caspase inhibitors and uses thereof
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU7593001A (en) Alpha-msh related compounds and methods of use
EP1283707A4 (en) Polymerizable compositions and methods of use
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
IL152116A0 (en) Prion-binding ligands and methods of using same
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU6340600A (en) Telomerase inhibitors and methods of their use
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU2001259817A1 (en) Methods of and compounds for inhibiting calpains
EP1194150A4 (en) Use of nitroxides in wound healing and in the prevention of photodamage
AU2001234962A1 (en) Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001268236A1 (en) Use of aicar and related compounds
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof